Ampersand Capital Partners today announced that MedPharm, a portfolio company of Ampersand Capital, has acquired Purna Pharmaceuticals NV, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms supporting pharmaceutical industry customers. The transaction establishes a strategic partnership between Purna and MedPharm to enhance trans-Atlantic capabilities in topical and transdermal pharmaceutical development and manufacturing.
